Chinese biotech aims $232M in IPO cash to push next-gen prostate cancer drug; Immunomedics raises nearly a half-billion off approval
→ A Chinese cancer-focused biotech looking to one-up J&J and Pfizer in castration-resistant prostate cancer has launched its IPO in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
